Domainex

Domainex is a drug discovery service company based in Cambridge UK providing protein expression, assay development and screening, hit generation (fragment/virtual screening), and integrated medicinal chemistry incorporating in vitro pharmacology, in vivo DMPK, computational design and synthetic/analytical chemistry. 

Company Type
Twitter Account
@Domainex_UK
News Page URL
Click here

Epidarex Capital

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets within the UK and US. Epidarex funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.

Company Type
Twitter Account
#Epidarex
News Page URL
Click here

ERA Consulting

ERA is able to contribute at any stage of product development, from discovery, through process development, non-clinical and clinical aspects, to regulatory approval and beyond. One of our recognised specialities is the design of a regulatory strategy, to cover part or all of the development process. Thus, our services include the following: Regulatory due diligence exercises for in- or out-licensing, interactions with regulatory agencies, such as pre-IND, pre-BLA and scientific advice procedures, clinical trial applications, marketing authorisation applications, including eCTD submissions, post-approval amendments or variations, advice on process development, including validation, input on characterisation and control, consulting on non-clinical and clinical strategy, facility inspections and support for establishment licensing.

Company Type
Twitter Account
n/a
News Page URL
Click here

Femeda

Femeda is a UK based company focused on developing a range technically ground breaking medical devices for female urinary incontinence. 698 million women worldwide are affected by incontinence, yet many existing products focus on managing and treating the symptoms of urinary incontinence, rather than the underlying cause.

Femeda is focused on the launch of Pelviva™, a unique patented disposable medical device for the treatment of female incontinence. Pelviva™, uses reactive pulse technology to strengthen weak pelvic floor muscles to prevent leaks and control urge incontinence. Pelviva™ has been shown to clinically improve bladder control in 84% of women after 12 weeks of treatment.

Company Type
Twitter Account
@FemedaLtd
News Page URL
Click here

Fusion Antibodies

Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services
- Antibody Engineering Services
- Antibody sequencing Services
- Protein Expression & Purification Services
- Monoclonal Antibody services BLAST & Standard
- cGMP Services

The Journey to IPO


Company Type
Twitter Account
@FsnAntibodies
News Page URL
Click here

IAG - Image Analysis Group

IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.

IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.

Company Type
Twitter Account
@ImageAnalysisUK
News Page URL
Click here

IDACO Consulting

Strategic pharmaceutical and pre-clinical consulting services. Critical due diligence, rationalisation and evaluation of IP portfolios, academic research and early-stage/preclinical projects - ultimately looking to de-risk and increase commercial attractiveness and licensing potential.
Advising and supporting academic institutions and start-up companies on out-sourcing strategies - looking for cost-effective solutions and accelerating the speed of progression and completion of projects.
Oversight and management of outsourced CMC and preclinical projects.
Undertaking due diligences on behalf of organisations in- and out-licencing development drug candidates.
Exploring innovative business models and opportunities for funding between academia and the out-sourcing network, looking to create collaborative win-win partnerships to progress projects.
Attending conferences and exhibitions on behalf of clients, evaluating new product opportunities and service providers.
Source: LinkedIn

Company Type
Keywords
Twitter Account
@IDACOConsulting
News Page URL
Click here

Illetrop

Illetrop provides hands-on senior executive support to biotechnology companies. Based in Scotland but operating internationally, Illetrop represents a number of companies from the UK, Asia and mainland Europe.

Company Type
Twitter Account
n/a
News Page URL
Click here

Intract Pharma

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Company Type
Keywords
Twitter Account
@intractpharma
News Page URL
Click here

Isogenica Ltd

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.